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Summary Resistance to cytotoxic agents may be encountered during the treatment of acute myeloblastic
leukaemia (AML). P-glycoprotein encoded by the MDR-] gene has been implicated as a potential drug
resistance mechanism in leukaemic cells. In recent years, many data have been accrued concerning the
expression of P-glycoprotein in leukaemia, and several studies have been published which have related MDR
status to outcome in AML. Conclusions as to the effect of P-glycoprotein expression on prognosis in AML
have varied widely. The studies are not immediately comparable, since they differ in methodology, treatment
regimens, demographic profile and, perhaps most importantly, criteria for positivity of MDR status. The
technique of statistical overview (meta-analysis) can be used to pool observational studies. Application of this
statistical method to existing studies suggests an estimated relative risk of 0.68 for P-glycoprotein expression
with respect to complete remission in AML. Further large studies are required to determine fully the role of
P-glycoprotein in AML.
A significant limiting factor in the successful treatment of
haematological malignancies is the phenomenon of drug re-
sistance to cytotoxic agents. The refractory nature of these
diseases may be evident at presentation, i.e. intrinsic resis-
tance, or conversely the tumour may be initially chemosensi-
tive but acquire resistance at relapse. Most cancers are
treated with multiagent regimens and so resistant disease is
associated with a loss of chemosensitivity to a wide spectrum
of structurally unrelated cytotoxic drugs. This phenomenon
was first observed in vitro by Biedler and Riehm (1970), and
the term 'multidrug resistance' (MDR) was coined. Cellular
acquisition of the MDR phenotype results in resistance to the
vinca alkaloids, anthracyclines and epipodophyllotoxins. The
advent of molecular biological techniques has led to the
discovery that there exists within the mammalian genome a
family of MDR genes. In man, there are two MDR genes,
MDR-J and MDR-3. The function of the protein encoded by
the MDR-3 gene is unknown. The MDR-J gene encodes for a
transmembranous glycoprotein (P-170). Transfection of the
MDR-1 DNA into drug-sensitive cells confers the MDR
phenotype (Chen et al., 1986; Ueda et al., 1987). P-170 acts
as an ATP-dependent efflux pump, leading to a decreased
intracellular concentration of drugs and cell survival in the
presence of normally lethal doses ofcytotoxic agents (Juliano
& Ling, 1976). Much in vitro evidence has accumulated sup-
porting the role of P-170 as a drug resistance mechanism in
tumour cells (Bradley et al., 1988).
In the last 5 years, investigators have looked for evidence
of P-170 in clinical samples. In that time, many data have
been amassed, on both solid tumours and leukaemias
(Nooter & Herweijer, 1991). Particular attention has focused
on acute leukaemia, since a homogeneous population of blast
cells is readily obtained from peripheral blood and bone
marrow.
Theoretically, any malignant cell can attain a drug-
resistant state by either a quantitative or qualitative change
in P-170. To date, there have been no convincing reports of
MDR-J gene amplification in human leukaemia. Although
the number of leukaemic cases studied is small, there have
been no reports of point mutations within the gene (Gekeler
et al., 1991; Holmes et al., 1992). In contrast, several studies
have identified MDR-J RNA up-regulation or increased P-
170 expression in acute myeloblastic leukaemia (AML) and,
in addition, have attempted to relate these parameters to
outcome in AML (see Table I). The role of the MDR-1 gene
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in conferring drug resistance in AML is unclear. The purpose
of this article is to review those studies which have inves-
tigated the prognostic significance of MDR-J gene expression
in AML and to adopt the statistical technique of 'meta-
analysis' in an attempt to draw a conclusion on this question.
Statistical analysis
To date, 12 studies have investigated the relationship between
P-170 expression and outcome in AML (see Table I). The
two largest studies (Ball et al., 1990; Willman et al., 1992)
have only appeared in abstract form, but both draw the
conclusion that P-170 expression is not a prognostic factor in
AML. The majority of the remaining ten investigations con-
clude that P-170 influences outcome. The overall analysis of
these data is hampered by methodological and technical con-
siderations. For example, four studies have measured MDR-J
RNA levels, five have investigated protein expression and
three studies have analysed both RNA and protein. Even
within each group, there is a lack of homogeneity. RNA may
be measured by Northern blot, slot blot, semiquantitative
polymerase chain reaction, RNAse protection assay or
RNA-RNA hybridisation methods. P-170 may be assayed
by flow cytometry or immunochemistry. A selection of DNA
probes and anti-P-170 monoclonal antibodies have been used
and, perhaps more importantly, differing criteria for the
definition of RNA and protein overexpression have been
chosen. In addition, treatment regimens have varied and the
demographic profile of patient populations have differed,
both of which may have influenced outcome. Can these very
different studies, which have all attempted to answer the
same question, be combined to make a useful estimate of the
average effect?
The statistical overview (or 'meta-analysis') in theory
allows an objective, coordinated assessment of all studies or
trials which have focused on the same clinical question (Peto,
1987). The technique of the statistical overview is being
widely introduced in reviewing medical literature. Ap-
plications usually relate to trials, but there is no reason in
principle why the technique could not be employed in pool-
ing reports of observational studies. An important considera-
tion is that all available data should be included in the
analysis. We have attempted to collate all relevant data and
have approached workers in the field for details of studies
described only in abstract and for any unpublished
results.
This overview is based on 12 studies, four of which cur-
rently exist only in abstract form. For each study, the out-
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come has been summarised as a relative risk (with 95%
confidence interval) for complete remission. Studies are sum-
marised in chronological order in the accompanying table
(Table II). The subtotals show the pooled relative risk of all
fully published studies. Detailed data are not available for
the two largest studies (Ball et al., 1990; Willman et al.,
1992): both abstracts report no effect of P-170 expression on
outcome, so the total number of observed patients has been
distributed to balance P-170-positive and P-170-negative
groups. For complete remission (see Figure 1) ten studies
give complete results, suggesting an overall relative risk (RR)
of 0.50 (95% confidence interval 0.43-0.59). Inclusion of the
two largest studies reported only in abstract suggests a more
conservative RR of 0.68 (0.60-0.70). Attempts at subdivision
of the studies into less heterogeneous groups have been
undertaken. For example, separate calculation of the relative
risk for RNA and protein expression yields figures of 0.69
and 0.68 respectively. Further meaningful subdivision is not
possible. In all of these estimates of relative risk, whether or
not including estimates of the effect of the two largest
'negative' studies, the upper 95% confidence intervals are
below 1.0, suggesting 'significant' difference in remission rates
between MDR-positive and MDR-negative patients.
Discussion
Correct interpretation of the contribution of small studies
has important consequences on future research and clinical
practice. All fully reported studies (499 patients), seven of
which were significant individually at the P<0.05 level, sug-
gested that the numbers in remission were higher in MDR-
negative patients. Abstracts of two larger studies (with 360
patients) reported no such benefits.
Concerns over the effect of publication bias (Begg & Ber-
lin, 1988) imply that it is relevant to consider to what extent
the 'negative' findings among 360 patients affect the
estimated effect of the published reports of 499 patients. It
would appear that in the case of MDR status the unpub-
lished data may reduce the 'size' of the effects (revising
relative risk of remission from 0.50 to 0.68) without making
it 'non-significant'. There remains, however, the possibilities
that we have not estimated correctly for the two abstracts in
this overview and that there are further 'negative' studies that
have not even been reported as abstracts. On present
evidence, however, it seems that MDR status is associated
with improved remission rates and that the estimated relative
risk (P-170 positive/P-170 negative) is approximately 0.7.
Table I MDR status vs outcome in AML
No. of
patients RNA/protein Significance?'
I Kuwazuru et al. (1990) 17 Protein Yes
2 Sato et al. (1990) 33 RNA Yes
3 Marie et al. (1991) 36 RNA Yes
4 Musto et al. (1991) 12 Protein
5 Pirker et al. (1991) 63 RNA Yes
6 Campos et al. (1992) 150 Protein Yes
7 Gruber et al. (1992) 34 RNA No
8 Wittebol et al. (1992)* 53 RNA/protein Yes
9 Wood et al. (1992)* 50 Protein No
10 Zhou et al. (1992) 51 RNA/protein Yes
11 Ball et al. (1990)* 205 Protein No
12 Willman et al. (1992)* 155 RNA/protein No
aAt P<0.05. *Abstract.
Table II Cohort studies showing relationship between MDR status and
remission
MDR remission
MDR RR (95% confidence
+ - interval)
I Kurazuru et al. (1990) 2/9 7/8 0.25 (0.07, 0.87)
(n = 17)
2 Sato et al. (1990) 10/17 14/16 0.67 (0.43, 1.04)
(n = 33)
3 Marie et al. (1991) 7/24 8/12 0.44 (0.21, 0.92)
(n = 36)
4 Musto et al. (1991) 2/2 10/10 1 (0.3, 3.6)
(n = 12)
5 Pirker et al. (1991) 24/45 16/18 0.60 (0.44, 0.83)
(n = 63)
6 Campos et al. (1992) 23/71 64/79 0.40 (0.28, 0.57)
(n = 150)
7 Gruber et al. (1992) 9/14 15/20 0.86 (0.54, 1.30)
(n = 34)
8 Wittebol et al. (1992) 7/25 21/28 0.37 (0.19, 0.72)
(n = 53)
9 Zhou et al. (1992) 11/29 17/22 0.49 (0.29, 0.82)
(n = 51)
10 Wood et al. (1992) 10/25 20/25 0.50 (0.30, 0.84)
(n = 50)
Subtotals 105/261 192/238 0.50 (0.43, 0.59)
11 Ball et al. (1990) 61/102 61/103 1.01 (0.81, 1.27)
(n = 205)
12 Willman et al. (1990) 46/77 46/78 1.01 (0.78, 1.31)
(n = 155)
Totals 212/440 299/419 0.68 (0.60, 0.70)384 J.A. HOLMES & R.R. WEST
Study No. of patients
Kuwazura etal. (1990) 17
Sato etal. (1990) 33
Marieetal.(1991) 36
Mustoetal.(1991) 12
Pirkeretal.(1991) 63
Camposetal.(1992) 150 -
Gruberetal.(1992) 34
Witteboletal.(1992) 53
Wood etal. (1992) 50
Zhou etal. (1992) 51
Subtotal 499 +
Ball etal. (1990) 205
Willman etal. (1992) 155
Total 859 -
0.01 0.1 1 4
Relative risk (log scale)
Figure 1 Cohort studies showing relationship between MDR
status and remission in acute myeloblastic leukaemia.
If it can be demonstrated that expression of P-170 is
instrumental in the attainment of a refractory state by
leukaemic cells, then it would be worthwhile exploring in
detail those compounds which have the ability to block this
effect. Many such classes of drug exist. It is possible that
leukaemic cells may employ more than one drug resistance
mechanism in their struggle for survival. Existing data do
suggest a role for P-glycoprotein in this respect. The
relevance of other mechanisms has yet to be established.
We would like to thank Nicholas Hartley for his help with the
statistical analysis and Sandra Gee and Christine Vincent for
secretarial help.
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